Wall Street Experts
ver. ZuMIgo(08/25)
Prognozy (mln) dla NeoPharm CO., LTD.
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
| Przychód (średnia) |
120,000.00 |
145,000.00 |
165,000.00 |
| Przychód Δ r/r |
0.00% |
20.83% |
13.79% |
| Przychód (min) |
119,800.66 |
145,000.00 |
165,000.00 |
| Przychód (max) |
120,199.34 |
145,000.00 |
165,000.00 |
| EBITDA (średnia) |
35,515.72 |
42,914.83 |
48,834.12 |
| EBIT (średnia) |
33,213.71 |
40,133.23 |
45,668.85 |
| EBIT % |
27.68% |
27.68% |
27.68% |
| Zysk netto (średni) |
21,874.30 |
28,686.07 |
33,902.42 |
| Zysk netto % |
18.23% |
19.78% |
20.55% |
| EPS (średnia) |
1398.50 |
1834.00 |
2167.50 |
| Liczba analityków (Przychody) |
2 |
1 |
1 |
| Liczba analityków (EPS) |
1 |
1 |
1 |
| symbol |
092730.KQ |
092730.KQ |
092730.KQ |